IMFINZI + chemo significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Ph 3 trial June 6, 2023
Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients May 31, 2023
Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1L NSCLC May 31, 2023
Promising New Clinical Data Announced from Triple Combination Therapy in INSIGHT-003 Trial May 31, 2023
Update of Ongoing Ph 1 Study of Voruciclib +/- Venetoclax in Patients with AML or B-Cell Malignancies Announced May 31, 2023
FAILED TRIAL: Ph 3 SAPPHIRE study of sitravatinib + (OPDIVO) vs docetaxel in patients with 2/3L advanced NSQ-NSCLC did not meet primary endpoint of OS May 31, 2023
KEYTRUDA + LENVIMA Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as 1L Treatment for Patients With Advanced RCC May 31, 2023
TAGRISSO + chemo demonstrated strong improvement in PFS for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial May 31, 2023
IMFINZI + LYNPARZA and IMFINZI alone both significantly improved PFS in advanced endometrial cancer when added to chemotherapy May 31, 2023
New Results from Ph 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an ADC May 18, 2023
ELAHERE® Demonstrates OS Benefit in the Ph 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer May 10, 2023
Updated Results from ORIENT-31 Study of Sintilimab + Chemo +/- Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated nsqNSCLC announced May 10, 2023
TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi in R/R FL and MCL Meet Primary Endpoint of ORR May 10, 2023
First Results from Ph 2 SunRISe-1 Study of TAR-200 and Cetrelimab in Patients with BCG-Unresponsive NMIBC announced May 10, 2023
Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME announced May 10, 2023
Early Positive IMX-110 Interim Data shows 100% Tumor Shrinkage in Advanced mCRC at the Lowest Dose of IMX-110 + Tislelizumab May 10, 2023
Positive Early Results from Global Randomized Ph 1b/2 Combination Study of TPST-1120 in 1L HCC announced May 10, 2023
Positive Preliminary Data announced from ADVANCED-1 Ph 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Ph 2 Clinical Development May 10, 2023
Positive final results from Ph 2 trial of VB10.16 + atezolizumab in advanced cervical cancer announced April 27, 2023
KEYTRUDA + Chemo Significantly Improved OS Compared to Chemo Alone in Patients With Advanced or Unresectable Biliary Tract Cancer April 20, 2023
mRNA-4157 (V940) + KEYTRUDA combination Demonstrated Superior RFS in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection vs KEYTRUDA April 20, 2023
